{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:23:16Z","timestamp":1761844996392,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["1R01HL139582-01A1"],"award-info":[{"award-number":["1R01HL139582-01A1"]}]},{"name":"Veterans Affairs Merit","award":["000900-01"],"award-info":[{"award-number":["000900-01"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31770864","81373869","81600277"],"award-info":[{"award-number":["31770864","81373869","81600277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.atherosclerosis.2019.04.211","type":"journal-article","created":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T09:40:56Z","timestamp":1555234856000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evacetrapib reduces pre\u03b2-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes"],"prefix":"10.1016","volume":"285","author":[{"given":"Yunqin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ecl.2014.08.001","article-title":"Beginning to understand high-density lipoproteins","volume":"43","author":"Santos-Gallego","year":"2014","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-2275(20)43114-1","article-title":"The plasma lecithins:cholesterol acyltransferase reaction","volume":"9","author":"Glomset","year":"1968","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib3","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin","volume":"48","author":"McKenney","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib8","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1021\/bi00401a005","article-title":"Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein","volume":"27","author":"Castro","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib14","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1016\/S0021-9258(18)83541-4","volume":"264","author":"Francone","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1194\/jlr.M041038","article-title":"Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma","volume":"55","author":"Miyazaki","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib16","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0022-2275(20)32370-1","article-title":"A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels","volume":"41","author":"Miyazaki","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0005-2760(93)90253-6","article-title":"Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations","volume":"1169","author":"Asztalos","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12986-016-0093-y","article-title":"Human serum prebeta1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases","volume":"13","author":"Chen","year":"2016","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2017.04.008","article-title":"Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial","volume":"261","author":"Nicholls","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1194\/jlr.M018010","article-title":"Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib","volume":"53","author":"Krauss","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ahj.2011.11.017","article-title":"Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study","volume":"163","author":"Ballantyne","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib23","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2015.09.013","article-title":"Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib","volume":"66","author":"Nicholls","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jacl.2016.06.006","article-title":"Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses","volume":"10","author":"van Capelleveen","year":"2016","journal-title":"Journal of clinical lipidology"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0021-9150(88)90094-9","article-title":"Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity","volume":"70","author":"Yamashita","year":"1988","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(00)00643-2","article-title":"Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease","volume":"156","author":"Asztalos","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1194\/jlr.M017079","article-title":"Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI","volume":"53","author":"Ji","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1194\/jlr.M700506-JLR200","article-title":"Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I","volume":"49","author":"Duong","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib29","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","article-title":"Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities","volume":"33","author":"Camont","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib30","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bbalip.2013.07.009","article-title":"Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles","volume":"1831","author":"Stahlman","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1194\/jlr.M076927","article-title":"Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate","volume":"59","author":"Persegol","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5551\/jat.38844","article-title":"Association of high-density lipoprotein subclasses with carotid intima-media thickness: shimane CoHRE study","volume":"25","author":"Notsu","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5551\/jat.ED072","article-title":"HDL3 cholesterol levels in an elderly population","volume":"25","author":"Inazu","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib34","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/11905","article-title":"Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency","volume":"22","author":"Brooks-Wilson","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/11914","article-title":"The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease","volume":"22","author":"Bodzioch","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/11921","article-title":"Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1","volume":"22","author":"Rust","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib38","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJM197811302992207","article-title":"Plasma high-density lipoproteins","volume":"299","author":"Tall","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI115028","article-title":"Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia","volume":"87","author":"Brinton","year":"1991","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cmet.2008.03.001","article-title":"HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis","volume":"7","author":"Tall","year":"2008","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1194\/jlr.M074625","article-title":"Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport","volume":"58","author":"Kuwano","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11883-011-0177-0","article-title":"Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux","volume":"13","author":"Santos-Gallego","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib43","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1373\/clinchem.2003.029207","article-title":"Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men","volume":"50","author":"Hattori","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.107.157123","article-title":"Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib46","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","article-title":"High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study","volume":"24","author":"Asztalos","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.04.211_bib47","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019303661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019303661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:39:08Z","timestamp":1758155948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019303661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":47,"alternative-id":["S0021915019303661"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.04.211","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evacetrapib reduces pre\u03b2-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.04.211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}